Sio Gene Therapies Inc (fka SIOX)

[georgejjl]

NEWS regarding SIOX

https://finance.yahoo.com/news/sio-gene-therapies-present-data-113000498.html

Good luck and GOD bless,

[georgejjl]

A MUST WATCH AND LISTEN!!!

https://wsw.com/webcast/cantor12/siox/2117150

Good luck and GOD bless,

[georgejjl]

Today's 8K filing with the US SEC

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001636050/000163605021000076/siox-20210923.htm

Good luck and GOD bless,

[georgejjl]

Expect the SIOX share price to double or triple or more by or before the end of October 2021.

Good luck and GOD bless,

[georgejjl]

09.23.2021
Sio Gene Therapies to Participate in Upcoming Conferences

https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-participate-upcoming-conferences-0

Good luck and GOD bless,

[georgejjl]

AXO-Lenti-PD

•SIO plans to move to the third higher dose cohort in the study after which it expects to initiate the randomised, sham-controlled part of the SUNRISE-PD Phase 2 study in 2022

• Sales of products to treat Parkinson’s disease in the 7 major markets reached $3.1bn in 2016 and is forecast to reach $8.4bn by 2026

AXO-Lenti-PD achieves up to 10-fold increases in dopamine + L-dopa production compared to ProSavin (OXB-101), without impacting infusion volume or rate of administration

https://www.oxb.com/system/files/corporate-presentations/OXB%20Presentation%204%20May%2021%20w%20appendix.pdf

Good luck and GOD bless,

[georgejjl]

we expect to report 12-month topline safety, biomarker, and clinical outcomes data from the Type II low-dose cohort of AXO-AAV-GM1 in October 2021.”

https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-dosing-first-gm1-gangliosidosis

Good luck and GOD bless,

[georgejjl]

“Dosing the first Type I patient represents a major milestone for the AXO-AAV-GM1 program and for the GM1 gangliosidosis community. The efforts by both Sio and our trial partners at the NIH are the culmination of our dedication to patients,” said Gavin Corcoran, M.D., Chief R&D Officer of Sio Gene Therapies. “We are excited to expand the age range of patients that have been dosed to address this more severe form of GM1 gangliosidosis, and we expect to report 12-month topline safety, biomarker, and clinical outcomes data from the Type II low-dose cohort of AXO-AAV-GM1 in October 2021.”

https://investors.siogtx.com/news-releases/news-release-details/sio-gene-therapies-announces-dosing-first-gm1-gangliosidosis

Good luck and GOD bless,

[georgejjl]

Cohort 3 of the AXO-Lenti-PD trial is scheduled to start around the end of calendar 2021 or early 2022. Cohort 3 will be 3 times the concentration as the dose given to Cohort 2.

Cohort 2 (n=2 evaluable patients): Positive 6-month data
demonstrating 21-point mean improvement from baseline in
UPDRS III “OFF” score

https://investors.siogtx.com/static-files/53b38274-3d1f-4d98-a157-93e04b94646a

Watch the video below regarding and ProSavin trial from Oxford BioMedica.

Good luck and GOD bless,

[Hobbydigger-53]

Hi guys, took profit from ATOSSA this morning and cashed in SIOX 2.10.
Think SP is still undervalued and worth a trade. Also nice targets to see: https://www.nasdaq.com/market-activity/stocks/siox/analyst-research
May be it needs some time but I´m very hopeful on SIOX.
HD

[jerseyboy]

Almost a nine percent gain today on higher-than-average volume. Hopefully something is up here! I'm glad I bought more early this week. I feel good about this company's long-term future.

[Ipeeinpools]

2.56 area is support, 2.98 area is major resistance, massive upside, we just need to break through!!

[conix]

SIOX chart

[jerseyboy]

I feel as though something good is happening here. Let's hope for a close over $3.00 this coming week.

[jerseyboy]

Wouldn't I like to see that! It would make my $3.15 basis look pretty good. I don't hold many biotechs any more because of the capricious way in which the FDA has been acting recently, but I still like this one for the long term.

[urge2surge]

You'd think corporate would release something??

[stocksrising]

Nice buy rate!!

2021-06-15 11:14:00 GMT DJ Sio Gene Therapies Price Target Announced at $8.00/Share by BTIG

[dinogreeves]

$8-10 dollars by end of July.

[stockguard]

AAV & Lentiviral Gene Therapies with Sio's Dr. Pavan Cheruvu Podcast

20_12_BPO_BusBiotech_Social_ep46
Fresh on the heels of a significant data readout on its AXO-AAV-GM1 candidate at the recent ASGCT meeting, Sio Gene Therapies CEO Pavan Cheruvu, M.D. joins the Business of Biotech podcast. We discuss Dr. Cheruvu's formative years and inspiration, his company's origins, its progress developing AAV and lentiviral gene therapies to treat GM1 gangliosidosis, Tay-Sachs / Sandhoff disease, and Parkinson's disease, and the challenges the company has overcome in a hybrid manufacturing environment that will ultimately transfer entirely in-house.

https://www.cellandgene.com/doc/aav-lentiviral-gene-therapies-with-sio-s-dr-pavan-cheruvu-0001?vm_tId=

[stockguard]

Sio Gene Therapies: Gene Therapies For Neurodegeneration
May 28, 2021 12:30 AM ETSio Gene Therapies, Inc. (SIOX)
https://seekingalpha.com/article/4431842-sio-gene-therapies-gene-therapies-for-neurodegeneration

[urge2surge]

Yeah what a dump. 8 dollar target upgrade to. Sop. Sheesh..

[stocksrising]

I guess the Anal’sts didn’t like what company was selling’ …or this was
Just a source of funds from Mkt sell off ? Anyhow, buying more on dip!!

[stockguard]

This week looking forward to:
Sio Gene Therapies Announces Four Upcoming Oral Presentations At 24th Annual Meeting Of American Society Of Gene And Cell Therapy

Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced four upcoming oral presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), to be held virtually between May 11th to May 14th, 2021.


The AXO-AAV-GM1 presentation will include a review of patient-level data on safety and efficacy at 6 months follow up from the low-dose cohort of the Company's ongoing clinical study. Additionally, Dr. Cynthia Tifft, the lead investigator for the study, will present 6-month biomarker data from cerebrospinal fluid (CSF) in the 5 children who received intravenous AAV9 gene therapy.

Oral Presentation Details:

Presentation Title: AXO-AAV-GM1 for the Treatment of GM1 Gangliosidosis: Preliminary Results from a Phase I-II trial

Abstract Number: 162

Session: Clinical Trials and Advanced Preclinical Studies for Neurologic Diseases

Presenting Author: Cynthia Tifft, MD, PhD, Deputy Clinical Director, National Human Genome Research Institute

Presentation Date and Time: Thursday, May 13, 2021 6:15 PM – 6:30 PM EDT

Presentation Title: AXO-Lenti-PD gene therapy for Parkinson's disease: efficacy, safety, and tolerability data from the second cohort in open-label dose evaluation study SUNRISE-PD at 6 months post administration

Abstract Number: 163

Session: Clinical Trials and Advanced Preclinical Studies for Neurologic Diseases

Presenting Author: Gavin Corcoran, MD, Chief R&D Officer

Presentation Date and Time: Thursday, May 13, 2021 6:30 PM – 6:45 PM EDT

Presentation Title: Immune Modulation Preceding AAV9-GLB1 Gene Therapy Preserves the Possibility for Re-Dosing in Children with GM1 Gangliosidosis

Abstract Number: 179

Session: Immunotherapy and Vaccines

Presenting Author: Precilla D'Souza, DNP, MSN, CRNP, National Human Genome Research Institute

Presentation Date and Time: Thursday, May 13, 2021 7:00 PM – 7:15 PM EDT

Presentation Title: A GLP Safety and Biodistribution Study of AXO-Lenti-PD Manufactured via Two Processes Delivered at a Higher Volume and Flow Rate

Abstract Number: 256

Session: Pharmacology/Toxicology Studies or Assay Development

Presenting Author: Thomas Pack, PhD, Sio Gene Therapies

Presentation Date and Time: Friday, May 14, 2021 from 1:45 PM – 2:00 PM EDT

About AXO-AAV-GM1

AXO-AAV-GM1 delivers a functional copy of the GLB1 gene via an adeno-associated viral (AAV) vector, with the goal of restoring ß-galactosidase enzyme activity for the treatment of GM1 gangliosidosis. The gene therapy is delivered intravenously, which has the potential to broadly transduce the central nervous system and treat peripheral manifestations of the disease as well. Preclinical studies in murine and a naturally-occurring feline model of GM1 gangliosidosis have supported AXO-AAV-GM1's ability to improve ß-galactosidase enzyme activity, reduce GM1 ganglioside accumulation, improve neuromuscular function, and extend survival.

AXO-AAV-GM1 has received both Orphan Drug Designation and Rare Pediatric Disease Designation from the Food and Drug Administration and is the only gene therapy in clinical development for both Type I and Type II GM1 gangliosidosis.

In 2018, Sio licensed exclusive worldwide rights from the University of Massachusetts Medical School for the development and commercialization of gene therapy programs for GM1 gangliosidosis and GM2 gangliosidosis, including Tay-Sachs and Sandhoff diseases.

About AXO-Lenti-PD

AXO-Lenti-PD is an investigational gene therapy for the treatment of Parkinson's disease that is designed to deliver three genes (tyrosine hydroxylase, cyclohydrolase 1, and aromatic L-amino acid decarboxylase) via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The investigational gene therapy aims to provide patient benefit for years following a single administration. Axovant expects to dose the first patient in EXPLORE-PD, a randomized, sham controlled study in 2021.

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[urge2surge]

8 dollar buy rating initiated. EOM.

[georgejjl]

Cohort 3 should be AMAZING with 3X the TU of Cohort 2

Volume Expansion
Cohort 3
4.2 x 107 TU
1800 µL total infusion volume

Gating item for filing
> Developing reliable, suspension-based manufacturing process
> Oxford Biomedica has initiated the manufacture of GMP batches
using this process

Oxford BioMedica should have capacity soon now that the Oxford/Astrazeneca vaccine production may be taking up less capacity at Oxford BioMedica.

Good luck and GOD bless,

[georgejjl]

Good things to come for SIOX

Click on the image below:



https://seekingalpha.com/article/4412262-why-taken-position-in-sio-gene-therapies

The next cohort will be much better.

Good luck and GOD bless,

[jerseyboy]

In response to the nice recent movement, I picked up some earlier this week. If they get their Parkinson's drug going, this is a $20.00 stock. Even without it, it's eventually at least a $5.00 stock. When it moves up, it moves fast.

[Big Beef]

I wish i had a Bigger piece of Sava lol

[jerseyboy]

There's some nice movement occurring here lately. I think this is one of most undervalued stocks in the biopharma arena. If they get their manufacturing kinks worked out and have a drug that is effective against Parkinson's disease, this will no longer be selling at $2.95.

[jerseyboy]

I just have a hunch that the languishing stock price in no way reflects the inherent value of this company. I'm thinking that it will be much more reflective of that value within a year.

[jerseyboy]

I think so, but they're volatile (look at ABEO as an example, although I still have confidence in their long-term prospects). If management is sound and stable and they have what appears to be a good pipeline that addresses significant unmet needs, I think they have the potential to be very rewarding. SIOX got punished for the snag in the manufacturing process development by Oxford, but I think it was unduly so and temporary, and I think its valuation is considerably lower than what it should be at this point, as $143.9 million seems to be much lower than comparable companies with similar prospects.

[stocksrising]

?? gene therapies are the space to be in it seems!

[jerseyboy]

I feel as though this is very undervalued with its market cap being what it is now compared with the potential of its pipeline. This will be much bigger than what it is currently being given credit for.

[stocksrising]

Lmao :) slayer!

[ClayTrader]

* * $SIOX Video Chart 12-16-2020 * *

Link to Video - click here to watch the technical chart video

[ipo_dude]

Yup

[stocksrising]

He was back in June, maybe his to focused on spacs! Lmao

[Docstemcell2020]

Is hunter on this board

[stocksrising]

Ohhh yeah ??.. anticipating the KOD to post on here soon( CT)

[CyrusDaVirus]

Boom guys congrats if you held today

[CyrusDaVirus]

Interesting movement here today. Looking for an entry for long

[stocksrising]

P*RVL takeout by Lilly should make this ticker bounce!

[TraderBel1968]

$GWSO - I wonder who makes the first buyout offer: $TSLO? $NKLA? or who?

"The company is in the final stages of filing a worldwide patent application for a new EV technology based on this sodium-based device.

“The first results we are seeing in our laboratory tests of new electrochemical cells are very encouraging,” says Artem Madatov, GWSO chief scientist. Calculations based on measurements of the cell characteristics showed a battery capacity of 8 MJ / kg. This means that with a battery weight of 300 kg (661 lbs.), a light truck can travel for about 750 miles on a single charge. Another important feature of our battery is the absence of the so-called "memory effect.” E.g.; during long-term operation of the battery, its electrical capacity does not decrease. Durability of the cathode and anode will allow recharging the battery about 2000 times. Thus, operating an EV for 1,500,000 miles will not require a battery change."

[jerseyboy]

Nice jump today - up almost 8%! Still a ways to go to my basis of $3.24 per share, but the share price recovery seems to be in progress.

[jerseyboy]

Hey georgejjl,

I just started a board for SIOX to reflect the symbol change from AXGT if you want to migrate over to it. Your contributions sound as though they would be valuable, as you seem to know something about what's going on with the company, probably much more than I do.

[keekee]

That P&D trade might have been complicated by my entry into the stock. If you read my other posts, you may understand why the stock is now under $2. Me!

[georgejjl]

The next cohort will be 3 times the concentration compared to Cohort 2

Cohort 2 had very good results. Look at the presentation.

https://www.sec.gov/Archives/edgar/data/1636050/000163605020000061/axgt8kex992102920.htm

https://www.sec.gov/Archives/edgar/data/1636050/000163605020000061/axgt8kex992102920.htm

Listen at

http://investors.axovant.com/investors/events-and-presentations

Good luck and GOD bless,

[georgejjl]

Axovant needs a PR to explain that Oxford BioMedica MUST dedicate capacity to produce adenovirus vectors for the Astrazeneca AZD1222 vaccine for Covid 19 and the Novartis Kymriah® cancer gene therapy.

This is a priority over the Parkinson's gene therapy for the Axovant trial.
The Axovant trial is very promising and is just delayed due to the covid 19 pandemic.

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-signs-supply-agreement-astrazeneca-expand-manufacturing

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-extends-commercial-supply-agreement-five-years-manufacture

https://www.oxfordbiomedica.co.uk/news-media/press-release/oxford-biomedica-notes-axovant-s-positive-six-month-follow-second-cohort

Good luck and GOD bless,

[SurgeGuy2.0]

$AXGT Have to just love it when CEO announces a delay with no indication of how long...real confidence builder!

Looks like the idiot MM on twitter is back again.....I hope they did not buy in too big before the massive drop! lolzzzzz

[INTL]

Good time to pay attention. Huge dip AH on 3rd party delay. Potential for a big bounce.